Emergence of co-resistance to imipenem/relebactam and ceftazidime/avibactam in clinical Klebsiella pneumoniae ST11 clone due to KPC-2 N132S and CTX-M-65 S130G/P167S substitutions
Antimicrobial Agents and Chemotherapy · 10.12.2025 · 69 (12)
DOI: 10.1128/aac.00891-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 10.12.2025. Verfasst von Yiqi Fu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Ceftazidime, Klebsiella pneumoniae, Azabicyclo Compounds, Imipenem. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Medical Science and Technology Project of Zhejiang Province.
Abstract (Originalsprache)
Two episodes of imipenem/relebactam and ceftazidime/avibactam co-resistant Klebsiella pneumoniae infections were identified in a Chinese hospital with an 8-month interval. All strains belonged to the ST11-KL64 clone, with pairwise SNP distances ranging from 1 to 9, indicating clonal spread. Plasmid-borne bla KPC-157 (KPC-2 N132S substitution) and bla CTX-M-249 (CTX-M-65 S130G/P167S substitutions) conferred resistance to imipenem/relebactam and ceftazidime/avibactam, respectively. The emergence of these novel resistance determinants in the high-risk clone underscores the need for enhanced surveillance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of M…
- Department of Respiration, Zhejiang Medical & Health Group Hangzhou Hospital, Hangzhou, China.
- Department of Food Science and Nutrition, College of Biosystems Engineering and Food Science, Zhejiang University, Hangzhou, China.
- Department of Laboratory Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Förderung
- National Natural Science Foundation of China
- Medical Science and Technology Project of Zhejiang Province
Zitieren
APA
Fu, Y., Zhang, Y., Zhao, J., Xie, J., Kong, H., Yang, T., Chen, W., & Xu, M. (2025). Emergence of co-resistance to imipenem/relebactam and ceftazidime/avibactam in clinical Klebsiella pneumoniae ST11 clone due to KPC-2 N132S and CTX-M-65 S130G/P167S substitutions. Antimicrobial Agents and Chemotherapy, 69(12). https://doi.org/10.1128/aac.00891-25
Vancouver
Fu Y, Zhang Y, Zhao J, Xie J, Kong H, Yang T, et al. Emergence of co-resistance to imipenem/relebactam and ceftazidime/avibactam in clinical Klebsiella pneumoniae ST11 clone due to KPC-2 N132S and CTX-M-65 S130G/P167S substitutions. Antimicrobial Agents and Chemotherapy. 2025;69(12). doi:10.1128/aac.00891-25
BibTeX
@article{Fu2025,
author = {Fu, Yiqi and Zhang, Yuchao and Zhao, Jun and Xie, Jiahong and Kong, Haishen and Yang, Tingting and Chen, Wei and Xu, Min},
title = {Emergence of co-resistance to imipenem/relebactam and ceftazidime/avibactam in clinical Klebsiella pneumoniae ST11 clone due to KPC-2 N132S and CTX-M-65 S130G/P167S substitutions},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
volume = {69},
number = {12},
doi = {10.1128/aac.00891-25}
}
EUVIMED